Cyclopharm achieves milestone with first USA patients imaged with technegas

Cyclopharm Limited (ASX: $CYC) has successfully imaged its first USA Technegas clinical patients at preeminent clinical sites in St Louis, Missouri and Stanford, California. This achievement follows the United States Food and Drug Administration approval of Technegas last October and the subsequent rollout of the company's plan for market penetration in medical facilities across the US.

Executive Commentary on USA Clinical Imaging Milestone

We are very pleased to see the clinical use of Technegas underway within days of installation and training at these sites and look forward to implementing Technegas to their affiliate locations in the coming months. Most significant is the fact that US patients are now benefitting from our Technegas technology, joining those in 64 other countries globally where our leading imaging solution is already established. We are grateful for the ongoing clinical guidance and partnership of the clinical leaders at these locations as well as for the support of the entire nuclear medicine and administration teams who have helped us navigate through the implementation process. We are very pleased that these sites are the first to use Technegas clinically in the United States.

Summary of Cyclopharm's Milestone Achievement

Cyclopharm Limited (ASX: $CYC) has achieved a significant milestone with the successful imaging of its first USA Technegas clinical patients. The company's CEO, James McBrayer, expressed his satisfaction with the rapid clinical use of Technegas at the two preeminent clinical sites and highlighted the immediate and ongoing clinical revenues for Technegas. With the approval of Technegas for clinical use in the United States, Cyclopharm is poised to expand its market presence and provide its leading imaging solution to more medical facilities. The company's mission to improve patient care outcomes through nuclear medicine and its core radiopharmaceutical product, Technegas, is now making a tangible impact in the US healthcare landscape. Cyclopharm looks forward to further implementing Technegas in affiliate locations and continuing its efforts to benefit patients globally with its innovative imaging technology.